StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 20 Apr 2023 09:05:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies http://www.streetinsider.com/Press+Releases/Biostax+Corp.+and+Statera+Biopharma%2C+Inc.+reach+mutually+beneficial+dispute+settlement+and+amended+license+agreement+providing+clearer+clinical+and+commercial+pathways+for+both+companies/21529726.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Biostax+Corp.+and+Statera+Biopharma%2C+Inc.+reach+mutually+beneficial+dispute+settlement+and+amended+license+agreement+providing+clearer+clinical+and+commercial+pathways+for+both+companies/21529726.html for the full story. http://www.streetinsider.com/Press+Releases/Biostax+Corp.+and+Statera+Biopharma%2C+Inc.+reach+mutually+beneficial+dispute+settlement+and+amended+license+agreement+providing+clearer+clinical+and+commercial+pathways+for+both+companies/21529726.html Thu, 20 Apr 2023 09:05:00 -0500 IMUN IMUND O.15717655 Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies http://www.streetinsider.com/Press+Releases/Biostax+Corp.+and+Statera+Biopharma%2C+Inc.+reach+mutually+beneficial+dispute+settlement+and+amended+license+agreement+providing+clearer+clinical+and+commercial+pathways+for+both+companies/21529726.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Biostax+Corp.+and+Statera+Biopharma%2C+Inc.+reach+mutually+beneficial+dispute+settlement+and+amended+license+agreement+providing+clearer+clinical+and+commercial+pathways+for+both+companies/21529726.html for the full story. http://www.streetinsider.com/Press+Releases/Biostax+Corp.+and+Statera+Biopharma%2C+Inc.+reach+mutually+beneficial+dispute+settlement+and+amended+license+agreement+providing+clearer+clinical+and+commercial+pathways+for+both+companies/21529726.html Thu, 20 Apr 2023 09:05:00 -0500 IMUN IMUND O.15717655 Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies http://www.streetinsider.com/Press+Releases/Biostax+Corp.+and+Statera+Biopharma%2C+Inc.+reach+mutually+beneficial+dispute+settlement+and+amended+license+agreement+providing+clearer+clinical+and+commercial+pathways+for+both+companies/21529726.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Biostax+Corp.+and+Statera+Biopharma%2C+Inc.+reach+mutually+beneficial+dispute+settlement+and+amended+license+agreement+providing+clearer+clinical+and+commercial+pathways+for+both+companies/21529726.html for the full story. http://www.streetinsider.com/Press+Releases/Biostax+Corp.+and+Statera+Biopharma%2C+Inc.+reach+mutually+beneficial+dispute+settlement+and+amended+license+agreement+providing+clearer+clinical+and+commercial+pathways+for+both+companies/21529726.html Thu, 20 Apr 2023 09:05:00 -0500 IMUN IMUND O.15717655 Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies http://www.streetinsider.com/Globe+Newswire/Biostax+Corp.+and+Statera+Biopharma%2C+Inc.+reach+mutually+beneficial+dispute+settlement+and+amended+license+agreement+providing+clearer+clinical+and+commercial+pathways+for+both+companies/21529726.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/Biostax+Corp.+and+Statera+Biopharma%2C+Inc.+reach+mutually+beneficial+dispute+settlement+and+amended+license+agreement+providing+clearer+clinical+and+commercial+pathways+for+both+companies/21529726.html for the full story. http://www.streetinsider.com/Globe+Newswire/Biostax+Corp.+and+Statera+Biopharma%2C+Inc.+reach+mutually+beneficial+dispute+settlement+and+amended+license+agreement+providing+clearer+clinical+and+commercial+pathways+for+both+companies/21529726.html Thu, 20 Apr 2023 09:05:00 -0500 IMUN IMUND O.15717655 Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies http://www.streetinsider.com/Globe+Newswire/Biostax+Corp.+and+Statera+Biopharma%2C+Inc.+reach+mutually+beneficial+dispute+settlement+and+amended+license+agreement+providing+clearer+clinical+and+commercial+pathways+for+both+companies/21529726.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/Biostax+Corp.+and+Statera+Biopharma%2C+Inc.+reach+mutually+beneficial+dispute+settlement+and+amended+license+agreement+providing+clearer+clinical+and+commercial+pathways+for+both+companies/21529726.html for the full story. http://www.streetinsider.com/Globe+Newswire/Biostax+Corp.+and+Statera+Biopharma%2C+Inc.+reach+mutually+beneficial+dispute+settlement+and+amended+license+agreement+providing+clearer+clinical+and+commercial+pathways+for+both+companies/21529726.html Thu, 20 Apr 2023 09:05:00 -0500 IMUN IMUND O.15717655 Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies http://www.streetinsider.com/Globe+Newswire/Biostax+Corp.+and+Statera+Biopharma%2C+Inc.+reach+mutually+beneficial+dispute+settlement+and+amended+license+agreement+providing+clearer+clinical+and+commercial+pathways+for+both+companies/21529726.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/Biostax+Corp.+and+Statera+Biopharma%2C+Inc.+reach+mutually+beneficial+dispute+settlement+and+amended+license+agreement+providing+clearer+clinical+and+commercial+pathways+for+both+companies/21529726.html for the full story. http://www.streetinsider.com/Globe+Newswire/Biostax+Corp.+and+Statera+Biopharma%2C+Inc.+reach+mutually+beneficial+dispute+settlement+and+amended+license+agreement+providing+clearer+clinical+and+commercial+pathways+for+both+companies/21529726.html Thu, 20 Apr 2023 09:05:00 -0500 IMUN IMUND O.15717655 Immune Therapeutics, Inc. Announces Shareholder Approval of Name Change to Biostax Corp. and Unveils New Website, Business Strategies and Direction http://www.streetinsider.com/Press+Releases/Immune+Therapeutics%2C+Inc.+Announces+Shareholder+Approval+of+Name+Change+to+Biostax+Corp.+and+Unveils+New+Website%2C+Business+Strategies+and+Direction/21304982.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Immune+Therapeutics%2C+Inc.+Announces+Shareholder+Approval+of+Name+Change+to+Biostax+Corp.+and+Unveils+New+Website%2C+Business+Strategies+and+Direction/21304982.html for the full story. http://www.streetinsider.com/Press+Releases/Immune+Therapeutics%2C+Inc.+Announces+Shareholder+Approval+of+Name+Change+to+Biostax+Corp.+and+Unveils+New+Website%2C+Business+Strategies+and+Direction/21304982.html Wed, 01 Mar 2023 09:34:00 -0500 IMUN IMUND O.15717655 Immune Therapeutics, Inc. Announces Shareholder Approval of Name Change to Biostax Corp. and Unveils New Website, Business Strategies and Direction http://www.streetinsider.com/Press+Releases/Immune+Therapeutics%2C+Inc.+Announces+Shareholder+Approval+of+Name+Change+to+Biostax+Corp.+and+Unveils+New+Website%2C+Business+Strategies+and+Direction/21304982.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Immune+Therapeutics%2C+Inc.+Announces+Shareholder+Approval+of+Name+Change+to+Biostax+Corp.+and+Unveils+New+Website%2C+Business+Strategies+and+Direction/21304982.html for the full story. http://www.streetinsider.com/Press+Releases/Immune+Therapeutics%2C+Inc.+Announces+Shareholder+Approval+of+Name+Change+to+Biostax+Corp.+and+Unveils+New+Website%2C+Business+Strategies+and+Direction/21304982.html Wed, 01 Mar 2023 09:34:00 -0500 IMUN IMUND O.15717655 Immune Therapeutics, Inc. Announces Shareholder Approval of Name Change to Biostax Corp. and Unveils New Website, Business Strategies and Direction http://www.streetinsider.com/Press+Releases/Immune+Therapeutics%2C+Inc.+Announces+Shareholder+Approval+of+Name+Change+to+Biostax+Corp.+and+Unveils+New+Website%2C+Business+Strategies+and+Direction/21304982.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Immune+Therapeutics%2C+Inc.+Announces+Shareholder+Approval+of+Name+Change+to+Biostax+Corp.+and+Unveils+New+Website%2C+Business+Strategies+and+Direction/21304982.html for the full story. http://www.streetinsider.com/Press+Releases/Immune+Therapeutics%2C+Inc.+Announces+Shareholder+Approval+of+Name+Change+to+Biostax+Corp.+and+Unveils+New+Website%2C+Business+Strategies+and+Direction/21304982.html Wed, 01 Mar 2023 09:34:00 -0500 IMUN IMUND O.15717655 Immune Therapeutics, Inc. Announces Shareholder Approval of Name Change to Biostax Corp. and Unveils New Website, Business Strategies and Direction http://www.streetinsider.com/Globe+Newswire/Immune+Therapeutics%2C+Inc.+Announces+Shareholder+Approval+of+Name+Change+to+Biostax+Corp.+and+Unveils+New+Website%2C+Business+Strategies+and+Direction/21304982.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/Immune+Therapeutics%2C+Inc.+Announces+Shareholder+Approval+of+Name+Change+to+Biostax+Corp.+and+Unveils+New+Website%2C+Business+Strategies+and+Direction/21304982.html for the full story. http://www.streetinsider.com/Globe+Newswire/Immune+Therapeutics%2C+Inc.+Announces+Shareholder+Approval+of+Name+Change+to+Biostax+Corp.+and+Unveils+New+Website%2C+Business+Strategies+and+Direction/21304982.html Wed, 01 Mar 2023 09:34:00 -0500 IMUN IMUND O.15717655 Immune Therapeutics, Inc. Announces Shareholder Approval of Name Change to Biostax Corp. and Unveils New Website, Business Strategies and Direction http://www.streetinsider.com/Globe+Newswire/Immune+Therapeutics%2C+Inc.+Announces+Shareholder+Approval+of+Name+Change+to+Biostax+Corp.+and+Unveils+New+Website%2C+Business+Strategies+and+Direction/21304982.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/Immune+Therapeutics%2C+Inc.+Announces+Shareholder+Approval+of+Name+Change+to+Biostax+Corp.+and+Unveils+New+Website%2C+Business+Strategies+and+Direction/21304982.html for the full story. http://www.streetinsider.com/Globe+Newswire/Immune+Therapeutics%2C+Inc.+Announces+Shareholder+Approval+of+Name+Change+to+Biostax+Corp.+and+Unveils+New+Website%2C+Business+Strategies+and+Direction/21304982.html Wed, 01 Mar 2023 09:34:00 -0500 IMUN IMUND O.15717655 Immune Therapeutics, Inc. Announces Shareholder Approval of Name Change to Biostax Corp. and Unveils New Website, Business Strategies and Direction http://www.streetinsider.com/Globe+Newswire/Immune+Therapeutics%2C+Inc.+Announces+Shareholder+Approval+of+Name+Change+to+Biostax+Corp.+and+Unveils+New+Website%2C+Business+Strategies+and+Direction/21304982.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/Immune+Therapeutics%2C+Inc.+Announces+Shareholder+Approval+of+Name+Change+to+Biostax+Corp.+and+Unveils+New+Website%2C+Business+Strategies+and+Direction/21304982.html for the full story. http://www.streetinsider.com/Globe+Newswire/Immune+Therapeutics%2C+Inc.+Announces+Shareholder+Approval+of+Name+Change+to+Biostax+Corp.+and+Unveils+New+Website%2C+Business+Strategies+and+Direction/21304982.html Wed, 01 Mar 2023 09:34:00 -0500 IMUN IMUND O.15717655 Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development http://www.streetinsider.com/Press+Releases/Immune+Therapeutics%2C+Inc.+Announces+Management+Change%3B+Moves+Forward+with+Repositioning+Strategy+and+Long-acting+TLR4+%28Toll+Like+Receptor+4%29+Antagonist+JKB-122+Development/20825214.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Immune+Therapeutics%2C+Inc.+Announces+Management+Change%3B+Moves+Forward+with+Repositioning+Strategy+and+Long-acting+TLR4+%28Toll+Like+Receptor+4%29+Antagonist+JKB-122+Development/20825214.html for the full story. http://www.streetinsider.com/Press+Releases/Immune+Therapeutics%2C+Inc.+Announces+Management+Change%3B+Moves+Forward+with+Repositioning+Strategy+and+Long-acting+TLR4+%28Toll+Like+Receptor+4%29+Antagonist+JKB-122+Development/20825214.html Wed, 09 Nov 2022 17:00:00 -0500 IMUN IMUND O.15717655 Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development http://www.streetinsider.com/Press+Releases/Immune+Therapeutics%2C+Inc.+Announces+Management+Change%3B+Moves+Forward+with+Repositioning+Strategy+and+Long-acting+TLR4+%28Toll+Like+Receptor+4%29+Antagonist+JKB-122+Development/20825214.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Immune+Therapeutics%2C+Inc.+Announces+Management+Change%3B+Moves+Forward+with+Repositioning+Strategy+and+Long-acting+TLR4+%28Toll+Like+Receptor+4%29+Antagonist+JKB-122+Development/20825214.html for the full story. http://www.streetinsider.com/Press+Releases/Immune+Therapeutics%2C+Inc.+Announces+Management+Change%3B+Moves+Forward+with+Repositioning+Strategy+and+Long-acting+TLR4+%28Toll+Like+Receptor+4%29+Antagonist+JKB-122+Development/20825214.html Wed, 09 Nov 2022 17:00:00 -0500 IMUN IMUND O.15717655 Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development http://www.streetinsider.com/Press+Releases/Immune+Therapeutics%2C+Inc.+Announces+Management+Change%3B+Moves+Forward+with+Repositioning+Strategy+and+Long-acting+TLR4+%28Toll+Like+Receptor+4%29+Antagonist+JKB-122+Development/20825214.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Immune+Therapeutics%2C+Inc.+Announces+Management+Change%3B+Moves+Forward+with+Repositioning+Strategy+and+Long-acting+TLR4+%28Toll+Like+Receptor+4%29+Antagonist+JKB-122+Development/20825214.html for the full story. http://www.streetinsider.com/Press+Releases/Immune+Therapeutics%2C+Inc.+Announces+Management+Change%3B+Moves+Forward+with+Repositioning+Strategy+and+Long-acting+TLR4+%28Toll+Like+Receptor+4%29+Antagonist+JKB-122+Development/20825214.html Wed, 09 Nov 2022 17:00:00 -0500 IMUN IMUND O.15717655 Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development http://www.streetinsider.com/Globe+Newswire/Immune+Therapeutics%2C+Inc.+Announces+Management+Change%3B+Moves+Forward+with+Repositioning+Strategy+and+Long-acting+TLR4+%28Toll+Like+Receptor+4%29+Antagonist+JKB-122+Development/20825214.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/Immune+Therapeutics%2C+Inc.+Announces+Management+Change%3B+Moves+Forward+with+Repositioning+Strategy+and+Long-acting+TLR4+%28Toll+Like+Receptor+4%29+Antagonist+JKB-122+Development/20825214.html for the full story. http://www.streetinsider.com/Globe+Newswire/Immune+Therapeutics%2C+Inc.+Announces+Management+Change%3B+Moves+Forward+with+Repositioning+Strategy+and+Long-acting+TLR4+%28Toll+Like+Receptor+4%29+Antagonist+JKB-122+Development/20825214.html Wed, 09 Nov 2022 17:00:00 -0500 IMUN IMUND O.15717655 Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development http://www.streetinsider.com/Globe+Newswire/Immune+Therapeutics%2C+Inc.+Announces+Management+Change%3B+Moves+Forward+with+Repositioning+Strategy+and+Long-acting+TLR4+%28Toll+Like+Receptor+4%29+Antagonist+JKB-122+Development/20825214.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/Immune+Therapeutics%2C+Inc.+Announces+Management+Change%3B+Moves+Forward+with+Repositioning+Strategy+and+Long-acting+TLR4+%28Toll+Like+Receptor+4%29+Antagonist+JKB-122+Development/20825214.html for the full story. http://www.streetinsider.com/Globe+Newswire/Immune+Therapeutics%2C+Inc.+Announces+Management+Change%3B+Moves+Forward+with+Repositioning+Strategy+and+Long-acting+TLR4+%28Toll+Like+Receptor+4%29+Antagonist+JKB-122+Development/20825214.html Wed, 09 Nov 2022 17:00:00 -0500 IMUN IMUND O.15717655 Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development http://www.streetinsider.com/Globe+Newswire/Immune+Therapeutics%2C+Inc.+Announces+Management+Change%3B+Moves+Forward+with+Repositioning+Strategy+and+Long-acting+TLR4+%28Toll+Like+Receptor+4%29+Antagonist+JKB-122+Development/20825214.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/Immune+Therapeutics%2C+Inc.+Announces+Management+Change%3B+Moves+Forward+with+Repositioning+Strategy+and+Long-acting+TLR4+%28Toll+Like+Receptor+4%29+Antagonist+JKB-122+Development/20825214.html for the full story. http://www.streetinsider.com/Globe+Newswire/Immune+Therapeutics%2C+Inc.+Announces+Management+Change%3B+Moves+Forward+with+Repositioning+Strategy+and+Long-acting+TLR4+%28Toll+Like+Receptor+4%29+Antagonist+JKB-122+Development/20825214.html Wed, 09 Nov 2022 17:00:00 -0500 IMUN IMUND O.15717655 Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors http://www.streetinsider.com/Press+Releases/Immune+Therapeutics+Appoints+H.+Louis+Salomonksy+to+its+Board+of+Directors/20631933.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Immune+Therapeutics+Appoints+H.+Louis+Salomonksy+to+its+Board+of+Directors/20631933.html for the full story. http://www.streetinsider.com/Press+Releases/Immune+Therapeutics+Appoints+H.+Louis+Salomonksy+to+its+Board+of+Directors/20631933.html Tue, 27 Sep 2022 14:57:00 -0500 A.07517608 A.08943700 IMUN IMUND O.03285401 O.15717655 O.20385233 Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors http://www.streetinsider.com/Press+Releases/Immune+Therapeutics+Appoints+H.+Louis+Salomonksy+to+its+Board+of+Directors/20631933.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Immune+Therapeutics+Appoints+H.+Louis+Salomonksy+to+its+Board+of+Directors/20631933.html for the full story. http://www.streetinsider.com/Press+Releases/Immune+Therapeutics+Appoints+H.+Louis+Salomonksy+to+its+Board+of+Directors/20631933.html Tue, 27 Sep 2022 14:57:00 -0500 A.07517608 A.08943700 IMUN IMUND O.03285401 O.15717655 O.20385233 Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors http://www.streetinsider.com/Press+Releases/Immune+Therapeutics+Appoints+H.+Louis+Salomonksy+to+its+Board+of+Directors/20631933.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Immune+Therapeutics+Appoints+H.+Louis+Salomonksy+to+its+Board+of+Directors/20631933.html for the full story. http://www.streetinsider.com/Press+Releases/Immune+Therapeutics+Appoints+H.+Louis+Salomonksy+to+its+Board+of+Directors/20631933.html Tue, 27 Sep 2022 14:57:00 -0500 A.07517608 A.08943700 IMUN IMUND O.03285401 O.15717655 O.20385233 Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors http://www.streetinsider.com/Press+Releases/Immune+Therapeutics+Appoints+H.+Louis+Salomonksy+to+its+Board+of+Directors/20631933.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Immune+Therapeutics+Appoints+H.+Louis+Salomonksy+to+its+Board+of+Directors/20631933.html for the full story. http://www.streetinsider.com/Press+Releases/Immune+Therapeutics+Appoints+H.+Louis+Salomonksy+to+its+Board+of+Directors/20631933.html Tue, 27 Sep 2022 14:57:00 -0500 A.07517608 A.08943700 IMUN IMUND O.03285401 O.15717655 O.20385233 Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors http://www.streetinsider.com/Press+Releases/Immune+Therapeutics+Appoints+H.+Louis+Salomonksy+to+its+Board+of+Directors/20631933.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Immune+Therapeutics+Appoints+H.+Louis+Salomonksy+to+its+Board+of+Directors/20631933.html for the full story. http://www.streetinsider.com/Press+Releases/Immune+Therapeutics+Appoints+H.+Louis+Salomonksy+to+its+Board+of+Directors/20631933.html Tue, 27 Sep 2022 14:57:00 -0500 A.07517608 A.08943700 IMUN IMUND O.03285401 O.15717655 O.20385233 Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors http://www.streetinsider.com/Press+Releases/Immune+Therapeutics+Appoints+H.+Louis+Salomonksy+to+its+Board+of+Directors/20631933.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Immune+Therapeutics+Appoints+H.+Louis+Salomonksy+to+its+Board+of+Directors/20631933.html for the full story. http://www.streetinsider.com/Press+Releases/Immune+Therapeutics+Appoints+H.+Louis+Salomonksy+to+its+Board+of+Directors/20631933.html Tue, 27 Sep 2022 14:57:00 -0500 A.07517608 A.08943700 IMUN IMUND O.03285401 O.15717655 O.20385233 Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors http://www.streetinsider.com/Press+Releases/Immune+Therapeutics+Appoints+H.+Louis+Salomonksy+to+its+Board+of+Directors/20631933.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Immune+Therapeutics+Appoints+H.+Louis+Salomonksy+to+its+Board+of+Directors/20631933.html for the full story. http://www.streetinsider.com/Press+Releases/Immune+Therapeutics+Appoints+H.+Louis+Salomonksy+to+its+Board+of+Directors/20631933.html Tue, 27 Sep 2022 14:57:00 -0500 A.07517608 A.08943700 IMUN IMUND O.03285401 O.15717655 O.20385233